Dominique Costantini
Founder at OSE IMMUNOTHERAPEUTICS
Profile
Dominique Costantini is the founder of Valerio Therapeutics SA (founded in 1997), Orphan Synergy Europe-Pharma SA (founded in 2004), OSE Pharmaceuticals (founded in 2012), and OSE Immunotherapeutics SA (founded in 2004).
She holds the title of Chief Executive Officer at Valerio Therapeutics SA and Orphan Synergy Europe-Pharma SA, and Chief Development & Strategy at OSE Immunotherapeutics SA. Her current job(s) include being a Director at Only For Children Pharmaceuticals SA and an Independent Director at Smart Immune SAS.
Her former job(s) include being the Chairman of CarThera SAS, an Independent Director at Theradiag SA, AB Science SA, and Sensorion SA, and a Director at Horama SA. She also worked as a Principal at Sanofi.
Dr. Costantini obtained a doctorate degree from Université de Paris 5 René Descartes.
Dominique Costantini active positions
| Companies | Position | Start |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Founder | 2004-11-16 |
| Only For Children Pharmaceuticals SA | Director/Board Member | - |
Smart Immune SAS
 Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Director/Board Member | - |
Former positions of Dominique Costantini
| Companies | Position | End |
|---|---|---|
| THERANEXUS | Director/Board Member | 2019-12-31 |
| ABIVAX | Director/Board Member | 2018-12-20 |
| VALERIO THERAPEUTICS | Chief Executive Officer | 2011-06-28 |
| OSE Pharmaceuticals | Chief Executive Officer | - |
| SENSORION | Director/Board Member | - |
Training of Dominique Costantini
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 7 |
|---|---|
| SANOFI | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| AB SCIENCE | Health Technology |
| SENSORION | Health Technology |
| THERANEXUS | Health Technology |
| ABIVAX | Health Technology |
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Private companies | 8 |
|---|---|
Theradiag SA
 Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
| Université de Paris 5 René Descartes | Consumer Services |
CarThera SAS
 CarThera SAS Medical SpecialtiesHealth Technology CarThera SAS develops ultrasound based medical devices to treat brain disorders. The firm offers SonoProbe and SonoCloud. The company was founded by Alexandre Carpentier on February 8, 2010 and is headquartered in Paris, France. | Health Technology |
Orphan Synergy Europe-Pharma SA
 Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Health Technology |
| Only For Children Pharmaceuticals SA | |
| OSE Pharmaceuticals | |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Health Technology |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Health Technology |
- Stock Market
- Insiders
- Dominique Costantini
